News
Displaying 1–10 of 548
-
SparingVision Completes Dosing in Gene-Agnostic Therapy Trial for Retinitis Pigmentosa (RP)
Research NewsNovel neuroprotective approach could benefit RP patients regardless of genetic mutation
-
Foundation News
The May 14 event will convene leaders across industries to raise funds that advance treatments and cures for blinding diseases.
-
Research News
Marking an important milestone for this rare form of retinitis pigmentosa (RP)
-
AAVantgarde Completes Enrollment in Retinal Gene Therapy Trial for Usher Syndrome Type 1B
Research NewsMilestone brings hope to patients with rare inherited retinal disease
-
Research News
First patient treated in Part B of ASTRA trial evaluating SB-007.
-
RD Fund Invests in Beacon Therapeutics to Advance XLRP Gene Therapy
Research NewsThe venture philanthropy arm of the Foundation partnered with other investors to support the development of a gene therapy trial for X-linked retinitis pigmentosa (XLRP).
-
Recording Available: Insights Forum | Friday, December 12, 2025
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on December 12, 2025.
-
Beacon Therapeutics Launches Clinical Trial for Bilateral Administration of XLRP Gene Therapy
Research NewsThe company has also fully enrolled the Phase 2/3 VISTA clinical trial for its XLRP gene therapy.
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
Opus Genetics Launches Gene Therapy Clinical Trial for Best Disease
Research NewsThe Foundation funded preclinical studies for the approach and launched Opus.
